-
公开(公告)号：US20120082673A1
公开(公告)日：2012-04-05
申请号：US13288286
申请日：2011-11-03
IPC分类号： A61K39/395 , A61P35/00 , G01N33/53 , C07K16/18 , C12N9/96
CPC分类号： C07K14/715 , A61K38/00
摘要： Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”
摘要翻译： 细胞因子及其受体已被证明在基础研究和治疗方面都是有用的。 本发明提供了称为“Zcytor16”的新的人细胞因子受体。
-
公开(公告)号：US20110002882A1
公开(公告)日：2011-01-06
申请号：US12762771
申请日：2010-04-19
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
摘要翻译： 描述了使用具有IL-21功能活性的分子治疗具有癌症的哺乳动物的方法。 具有IL-21功能活性的分子包括与人IL-21多肽序列具有同源性的多肽和与具有IL-21功能活性的多肽融合的蛋白质。 分子可以用作单一疗法或与其他已知的癌症治疗剂组合使用。
-
公开(公告)号：US07718172B2
公开(公告)日：2010-05-18
申请号：US11829765
申请日：2007-07-27
IPC分类号： A61K39/395 , C07K14/54 , C07K16/00 , C07K16/22
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/34
摘要： The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
摘要翻译： 本发明涉及阻断IL-TIF多肽分子的活性。 IL-TIF是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-TIF抗体和结合配偶体，以及在IL-TIF相关的人类炎性疾病中使用这样的抗体和结合伴侣拮抗IL-TIF的方法，以及其它用途。
-
公开(公告)号：US20090087404A1
公开(公告)日：2009-04-02
申请号：US12250911
申请日：2008-10-14
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
-
公开(公告)号：US20090022723A1
公开(公告)日：2009-01-22
申请号：US11829765
申请日：2007-07-27
IPC分类号： A61K39/395 , C12N5/06 , A61P29/00
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/34
摘要： The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
摘要翻译： 本发明涉及阻断IL-TIF多肽分子的活性。 IL-TIF是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-TIF抗体和结合配偶体，以及在IL-TIF相关的人类炎性疾病中使用这样的抗体和结合伴侣拮抗IL-TIF的方法，以及其它用途。
-
公开(公告)号：US09629798B2
公开(公告)日：2017-04-25
申请号：US12935114
申请日：2009-03-26
申请人： Richard I. Senderoff , Jeffrey D. Meyer , Emily N. Rollins , Steven D. Hughes , Richard M. Garcia , Paul D. Bishop , Gerald W. Lasser
发明人： Richard I. Senderoff , Jeffrey D. Meyer , Emily N. Rollins , Steven D. Hughes , Richard M. Garcia , Paul D. Bishop , Gerald W. Lasser
CPC分类号： A61K47/42 , A61K9/0024 , A61K9/06 , A61K38/4833 , A61K47/10 , A61K47/26 , A61K47/32 , A61K47/38 , C12Y304/21005 , Y10T428/2982
摘要： Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
-
7.发明授权Anti-IL-20 antibodies and binding partners and methods of using in inflammation 有权抗IL-20抗体和结合配偶体以及在炎症中使用的方法公开(公告)号：US08907068B2
公开(公告)日：2014-12-09
申请号：US12124946
申请日：2008-05-21
申请人： Wenfeng Xu , Wayne R. Kindsvogel , Zhi Chen , Steven D. Hughes , Yasmin A. Chandrasekher , Stacey R. Dillon , Joyce M. Lehner , Anthony W. Siadak , Pallavar V. Sivakumar , Margaret D. Moore
发明人： Wenfeng Xu , Wayne R. Kindsvogel , Zhi Chen , Steven D. Hughes , Yasmin A. Chandrasekher , Stacey R. Dillon , Joyce M. Lehner , Anthony W. Siadak , Pallavar V. Sivakumar , Margaret D. Moore
IPC分类号： C07K16/24 , A61K38/17 , A61K47/48 , C07K16/28 , C07K14/715 , C07K14/54 , A61K38/20 , A61K39/00
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
摘要翻译： 本发明涉及阻断IL-20多肽分子的活性。 IL-20是涉及炎症过程和人类疾病的细胞因子。 IL-20RA / IL-20RB是IL-20的常见受体。 本发明包括抗IL-20抗体和结合配偶体，以及使用这种抗体和结合配偶体拮抗IL-20的方法。
-
公开(公告)号：US08524227B2
公开(公告)日：2013-09-03
申请号：US12732116
申请日：2010-03-25
IPC分类号： A61K39/395 , C07K16/22 , C07K16/24 , C07K14/54 , C12P21/08
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/34
摘要： The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
摘要翻译： 本发明涉及阻断IL-TIF多肽分子的活性。 IL-TIF是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-TIF抗体和结合配偶体，以及在IL-TIF相关的人类炎性疾病中使用这样的抗体和结合伴侣拮抗IL-TIF的方法，以及其它用途。
-
公开(公告)号：US20120189628A1
公开(公告)日：2012-07-26
申请号：US12732116
申请日：2010-03-25
IPC分类号： A61K39/395 , A61P29/00 , C07K19/00 , C07K16/24 , C12N9/96
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/34
摘要： The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
摘要翻译： 本发明涉及阻断IL-TIF多肽分子的活性。 IL-TIF是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-TIF抗体和结合配偶体，以及在IL-TIF相关的人类炎性疾病中使用这样的抗体和结合伴侣拮抗IL-TIF的方法，以及其它用途。
-
10.发明申请公开(公告)号：US20110300098A1
公开(公告)日：2011-12-08
申请号：US12826099
申请日：2010-06-29
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
摘要翻译： 描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。 可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。 联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.05 秒)
